GlassScriptPhysician profile
Tony Catanzaro
NPI 1750395554
$6,918.55
in general payments reported to CMS, 2019-2025
25 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $242 · 2021: $376 · 2022: $1,091 · 2023: $1,421 · 2024: $886 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,362 · Long Term Medical Supply Or Device Loan: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,361.64 |
| Long Term Medical Supply Or Device Loan | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,097.23 | 2019-2025 | Idosetr, Idose, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $1,785.30 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Alcon Vision LLC | $993.09 | 2019-2025 | Clareon, Hydrus Microstent, Argos |
| Ocular Therapeutix, INC. | $530.81 | 2021-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $208.81 | 2020-2023 | |
| Genentech USA, INC. | $196.32 | 2022-2024 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $131.55 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $118.84 | 2019-2021 | |
| Oyster Point Pharma, INC. | $116.96 | 2022-2024 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $92.33 | 2023-2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Bausch & Lomb Americas INC. | $90.93 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $77.22 | 2019-2021 | |
| Sight Sciences, INC. | $74.71 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $72.85 | 2024-2025 | Xdemvy |
| Rxsight INC | $67.63 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $51.15 | 2024 | |
| Astellas Pharma US INC | $45.90 | 2025 | Izervay |
| Dompe US, INC. | $33.14 | 2025 | Oxervate |
| Lensar, INC. | $31.60 | 2023 | Lensar Laser System |
| Ivantis, INC | $22.92 | 2021 | |
| Shire North American Group INC | $18.41 | 2019 | |
| Thea Pharma INC. | $16.88 | 2023 | Iyuzeh |
| Ani Pharmaceuticals, INC. | $16.39 | 2025 | Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.58 | 2019 | |
| Omeros Corporation | $13.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Catanzaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.